Role of the molecular staging and response in the management of follicular lymphoma patients

References

• Horning S J. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20(Suppl 5)75–88
   PubMed Web of Science ®Google Scholar
• Weiss L M, Warnke R A, Sklar J, Cleary M L. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med 1987; 317: 1185–1189
   PubMed Web of Science ®Google Scholar
• Lopez-Guillermo A, Cabanillas F, McDonnell T I, McLaughlin P, Smith T, Pugh W, et al. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood 1999; 93: 3081–3087
   PubMed Web of Science ®Google Scholar
• Pezzella F, Jones M, Ralfkiaer E, Ersboll J, Gatter K C, Mason D Y. Evaluation of bcl-2 protein expression and 14;18 translocation as prognostic markers in follicular lymphoma. Br J Cancer 1992; 65: 87–89
   PubMed Web of Science ®Google Scholar
• Montoto S, Lopez-Guillermo A, Colomer D, Esteve J, Bosch F, Ferrer A, et al. Incidence and clinical significance of bcl-2/IgH rearrangements in follicular lymphoma. Leuk Lymphoma 2003; 44: 71–76
   PubMed Web of Science ®Google Scholar
• Rambaldi A, Lazzari M, Manzoni C, Carlotti E, Arcaini L, Baccarani M, et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002; 99: 856–862
   PubMed Web of Science ®Google Scholar
• Freedman A S, Neuberg D, Mauch P, Soiffer R J, Anderson K C, Fisher D C, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325–3333
   PubMed Web of Science ®Google Scholar
• Apostolidis J, Gupta R K, Grenzelias D, Johnson P W, Pappa V I, Summers K E, et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 2000; 18: 527–536
   PubMed Web of Science ®Google Scholar
• Magni M, Di Nicola M, Devizzi L, Matteucci P, Lombardi F, Gandola L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864–869
   PubMed Web of Science ®Google Scholar
• Lazzarino M, Arcaini L, Bernasconi P, Alessandrino E P, Gargantini L, Cairoli R, et al. A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol 2002; 116: 229–235
   PubMed Web of Science ®Google Scholar
• Voso M T, Pantel G, Weis M, Schmidt P, Martin S, Moos M, Ho A D, Haas R, Hohaus S. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 2000; 109: 729–735
   PubMed Web of Science ®Google Scholar
• Horsman D E, Gascoyne R D, Coupland R W, Coldman A J, Adomat S A. Comparison of cytogenetic analysis, southern analysis, and polymerase chain reaction for the detection of t(14; 18) in follicular lymphoma. Am J Clin Pathol 1995; 103: 472–478
   PubMed Web of Science ®Google Scholar
• Seite P, Hillion J, d'Agay M F, Gaulard P, Cazals D, Badoux F, et al. BCL2 gene activation and protein expression in follicular lymphoma: a report on 64 cases. Leukemia 1993; 7: 410–417
   PubMed Web of Science ®Google Scholar
• Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101–106
   PubMed Web of Science ®Google Scholar
• Johnson A, Brun A, Dictor M, Rambech E, Akerman M, Anderson H. Incidence and prognostic significance of t(14;18) translocation in follicle center cell lymphoma of low and high grade. A report from southern Sweden. Ann Oncol 1995; 6: 789–794
   PubMed Web of Science ®Google Scholar
• Yunis J J, Mayer M G, Arnesen M A, Aeppli D P, Oken M M, Frizzera G. bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med 1989; 320: 1047–1054
   PubMed Web of Science ®Google Scholar
• Gribben J G, Neuberg D, Barber M, Moore J, Pesek K W, Freedman A S, et al. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood 1994; 83: 3800–3807
   PubMed Web of Science ®Google Scholar
• Lopez-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Rodriguez M A, et al. The clinical significance of molecular response in indolent follicular lymphomas. Blood 1998; 91: 2955–2960
   PubMed Web of Science ®Google Scholar